EXCLUSIVE: Vivani Medical Tells Benzinga 'Study Represents the First Clinical Application of NanoPortal, the Company's Proprietary Drug Implant Platform Technology'
EXCLUSIVE: Vivani Medical Tells Benzinga 'Study Represents the First Clinical Application of NanoPortal, the Company's Proprietary Drug Implant Platform Technology'
獨家：Vivani 醫療告訴Benzinga '研究代表了NanoPortal的首次臨床應用，這是該公司的專有藥物植入平台科技'
EXCLUSIVE: Vivani Medical Tells Benzinga 'Study Represents the First Clinical Application of NanoPortal, the Company's Proprietary Drug Implant Platform Technology'
獨家：Vivani 醫療告訴Benzinga '研究代表了NanoPortal的首次臨床應用，這是該公司的專有藥物植入平台科技'
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間